Related Experiment Videos
Rapid switchover to carbamazepine using pharmacokinetic parameters
A M Kanner1, B F Bourgeois, H Hasegawa
1Rush Epilepsy Center and Department of Neurological Sciences, Rush Medical College, Chicago, Illinois 60612, USA.
Epilepsia
|May 13, 1998
Summary
Rapidly switching patients to carbamazepine (CBZ) is safe and effective, minimizing adverse effects (AE) and seizure increases. This method allows for precise dosing based on single-dose kinetic studies, proving beneficial for epilepsy management.
Area of Science:
- Pharmacology
- Clinical Neurology
- Epilepsy Management
Background:
- Standard carbamazepine (CBZ) initiation involves slow dose titration to mitigate adverse effects (AE).
- A pilot study introduced a protocol for rapid CBZ switchover using single-dose kinetic studies.
- This protocol aimed to manage concurrent tapering of previous antiepileptic drugs (AEDs) without inducing AE.
Purpose of the Study:
- To evaluate the safety and efficacy of a rapid switchover protocol to CBZ.
- To determine if predicted CBZ maintenance doses achieve target steady-state concentrations (Css).
- To assess necessary adjustments to CBZ maintenance doses after prior AED discontinuation.
Main Methods:
- Twenty-five patients on phenytoin (PHT), phenobarbital (PB), or primidone (PRM) underwent a 10 mg/kg single-dose kinetic study.
- Patients received escalating CBZ doses daily until the calculated maintenance dose was reached.
- Concurrent tapering of previous AEDs was initiated, with pharmacokinetic data and AE monitored.
Main Results:
- The switchover was completed in a mean of 6 days, achieving a mean CBZ maintenance dose of 1,639 mg/day and Css of 11.3 mg/l.
- 59% of patients required a 20.4% reduction in CBZ maintenance dose within four weeks post-discontinuation of prior AEDs.
- No patients experienced increased seizure frequency; 60% reported no AE, while 20% had mild AE. Severe AE occurred in patients with static encephalopathy or those ≥55 years.
Conclusions:
- Rapid switchover to CBZ from PHT, PB, or PRM is safe with minimal AE in young adults.
- The protocol is effective in achieving target CBZ concentrations.
- Patients with static encephalopathy or older adults may require careful monitoring due to increased risk of severe AE.